✦ LIBER ✦

Targeted therapy with erlotinib prolongs survival in NSCLC

✍ Scribed by James R. Rigas; Konstantin H. Dragnev

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

18 NSCLC second line therapy with erloti

✍ Urquhart, G.; Semple, E.; Steven, E.; Kerr, K.; Nicolson, M. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 34 KB

42IN ADVANCED NSCLC: MAINTENANCE WITH TA

✍ Gridelli, C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Salvage with erlotinib plus bevacizumab:

✍ Jean-Paul Sculier; Anne-Pascal Meert; Thierry Berghmans 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 150 KB

Targeted therapies: Bevacizumab and chem

✍ Vassileva, Vessela 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 80 KB

Retreatment with erlotinib in NSCLC harb

✍ Fiala, Ondrej; Pesek, Milos; Finek, Jindrich; Benesova, Lucie; Minarik, Marek 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 51 KB

24IN WILL STEREOTACTIC BODY RADIOTHERAPY

✍ Baumann, P.; Lewensohn, R. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 39 KB